OBJECTIVES: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. METHODS:sixteen geriatric depressed patients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. RESULTS: greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. CONCLUSIONS: lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression. 2011 American Association for Geriatric Psychiatry.
RCT Entities:
OBJECTIVES: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. METHODS: sixteen geriatric depressedpatients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. RESULTS: greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. CONCLUSIONS: lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression. 2011 American Association for Geriatric Psychiatry.
Authors: P F Renshaw; A M Parow; F Hirashima; Y Ke; C M Moore; B de B Frederick; M Fava; J Hennen; B M Cohen Journal: Am J Psychiatry Date: 2001-12 Impact factor: 18.112
Authors: A Wolkin; F Barouche; A P Wolf; J Rotrosen; J S Fowler; C Y Shiue; T B Cooper; J D Brodie Journal: Am J Psychiatry Date: 1989-07 Impact factor: 18.112
Authors: Sanjaya Saxena; Arthur L Brody; Matthew L Ho; Narineh Zohrabi; Karron M Maidment; Lewis R Baxter Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Gwenn S Smith; Charles F Reynolds; Patricia R Houck; Mary Amanda Dew; Yilong Ma; Benoit H Mulsant; Bruce G Pollock Journal: Am J Geriatr Psychiatry Date: 2002 Sep-Oct Impact factor: 4.105
Authors: Cynthia A Munro; Clifford I Workman; Elisse Kramer; Carol Hermann; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg; Gwenn S Smith Journal: Synapse Date: 2012-08-28 Impact factor: 2.562
Authors: Melissa Lamar; Michael Craig; Eileen M Daly; William J Cutter; Christine Tang; Michael Brammer; Katya Rubia; Declan G M Murphy Journal: Hum Brain Mapp Date: 2012-12-20 Impact factor: 5.038
Authors: Gwenn S Smith; Georg Oeltzschner; Neda F Gould; Jeannie-Marie S Leoutsakos; Najilla Nassery; Jin Hui Joo; Michael A Kraut; Richard A E Edden; Peter B Barker; S Andrea Wijtenburg; Laura M Rowland; Clifford I Workman Journal: J Affect Disord Date: 2020-10-07 Impact factor: 4.839